deucravacitinib vs Envudeucitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT03611751 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.
Next expected readout: November 2026 · NCT05570955 (registry estimate)
Reported efficacy
The Percentage of Participants With sPGA Response of 0 or 1 (At week 16); The Percentage of Participants With PASI 75 Response (At week 16): The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) (met)
Result source: NCT04167462
Envudeucitinib
Developed by Alumis and partners
NCT06586112 · Phase 3 · completed
Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2027 · NCT05739435 (registry estimate)
Reported efficacy
To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)
Result source: NCT06586112
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | deucravacitinib | Envudeucitinib |
|---|---|---|
| PASI 75 | 53% vs 9.4%+43.6 vs placeboNCT036117519 other results
| 56.4% vs 0%+56.4 vs placeboNCT056000364 other results
|
| PASI 90 | 27% vs 2.7%+24.3 vs placeboNCT036117512 other results
| —Not posted · NCT06588738 |
| PASI 100 | 10.2% vs 1.2%+9 vs placeboNCT036117512 other results
| —Not posted · NCT06588738 |
| sPGA 0/1 | 49.5% vs 8.6%+40.9 vs placeboNCT0361175111 other results
| 53.8% vs 7.9%+45.9 vs placeboNCT056000364 other results
|
| DLQI, change | -10.2 vs -2.9−7.3 vs placeboNCT029318384 other results
| —Not posted · NCT06588738 |
PASI 75
- deucravacitinib
- 53% vs 9.4%+43.6 vs placeboNCT03611751
9 other results
- 58.4% vs 12.7% NCT03624127
- 68.8% vs 8.1% NCT04167462
- 53% vs 39.8% NCT03611751
- 58.4% vs 35.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 66.7% vs 6.7% NCT02931838
- 9.1% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 68.9% vs 6.7% NCT02931838
- Envudeucitinib
- 56.4% vs 0%+56.4 vs placeboNCT05600036
4 other results
- 64.1% vs 0% NCT05600036
- 33.3% vs 0% NCT05600036
- 56.4% vs 0% NCT05600036
- 19.4% vs 0% NCT05600036
PASI 90
- deucravacitinib
- 27% vs 2.7%+24.3 vs placeboNCT03611751
2 other results
- 35.5% vs 4.2% NCT03624127
- 38.2% vs 1.4% NCT04167462
- Envudeucitinib
- —Not posted · NCT06588738
PASI 100
- deucravacitinib
- 10.2% vs 1.2%+9 vs placeboNCT03611751
2 other results
- 14.2% vs 0.6% NCT03624127
- 4.2% vs 0% NCT04167462
- Envudeucitinib
- —Not posted · NCT06588738
sPGA 0/1
- deucravacitinib
- 49.5% vs 8.6%+40.9 vs placeboNCT03611751
11 other results
- 53.6% vs 7.2% NCT03624127
- 55.6% vs 6.8% NCT04167462
- 49.5% vs 33.9% NCT03611751
- 53.6% vs 32.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 64.4% vs 6.7% NCT02931838
- 20.5% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 75.6% vs 6.7% NCT02931838
- 35.5% vs 8.2% NCT05701995
- 51% vs 4.3% NCT05478499
- Envudeucitinib
- 53.8% vs 7.9%+45.9 vs placeboNCT05600036
4 other results
- 59% vs 7.9% NCT05600036
- 38.9% vs 7.9% NCT05600036
- 48.7% vs 7.9% NCT05600036
- 16.7% vs 7.9% NCT05600036
DLQI, change
- deucravacitinib
- -10.2 vs -2.9−7.3 vs placeboNCT02931838
4 other results
- -8.4 vs -2.9 NCT02931838
- -3.8 vs -2.9 NCT02931838
- -6.1 vs -2.9 NCT02931838
- -9.7 vs -2.9 NCT02931838
- Envudeucitinib
- —Not posted · NCT06588738
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. deucravacitinib: 4 of 4 rows · Envudeucitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | deucravacitinib | Envudeucitinib |
|---|---|---|
| Dropout rate | 0.2%BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy 0%BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 9.6%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 0.8%Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 8.7%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 8.1%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 4.5%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 13.3%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 18.2%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 22.7%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence | 10.3%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results15.4%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.5%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 16.7%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 2.7%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 3.9%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 5.4%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 2.3%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 4.5%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence | 2.6%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 5.6%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results1.6%BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy 2.9%BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy 2.1%BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy 5.8%BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy —Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy 2.7%BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy 0%BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy 4.9%Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 2.5%Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence 4.3%Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 1%Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 6.8%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 0%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 0%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence | 0%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.7%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 2.8%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 10.8% (placebo 11.4%) upper respiratory tract infection 4.9% (placebo 4.3%) diarrhoea 4.7% (placebo 7.5%) NCT03611751 · Phase 3 · monotherapy show 15 more resultsnasopharyngitis 16% (placebo 11.4%) upper respiratory tract infection 8.9% (placebo 4.3%) headache 5.4% (placebo 5.5%) NCT03611751 · Phase 3 · monotherapy nasopharyngitis 6.3% (placebo 4.2%) upper respiratory tract infection 6.3% (placebo 3.6%) headache 4.8% (placebo 3%) NCT03624127 · Phase 3 · monotherapy nasopharyngitis 18.1% (placebo 4.2%) upper respiratory tract infection 9.4% (placebo 3.6%) headache 6.6% (placebo 3%) NCT03624127 · Phase 3 · monotherapy upper respiratory tract infection 17.8% (placebo 18.9%) mouth ulceration 7.5% (placebo 5.4%) nasopharyngitis 6.8% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy psoriasis 11.8% (placebo 2.7%) headache 5.9% (placebo 0%) nasopharyngitis 5.9% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy covid-19 9.7% (placebo 4.1%) upper respiratory tract infection 7.8% (placebo 2%) nasopharyngitis 3.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence acne 7.6% (placebo 4.1%) nasopharyngitis 6.7% (placebo 4.1%) covid-19 5.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.4% (placebo 17.8%) covid-19 12.8% (placebo 8.9%) upper respiratory tract infection 11.7% (placebo 6.7%) NCT05478499 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.5% (placebo 17.8%) upper respiratory tract infection 11.7% (placebo 6.7%) acne 9.7% (placebo 2.2%) NCT05478499 · Phase 4 · registry result, not featured evidence 6 mg QD nasopharyngitis 31.1% acne 9.5% constipation 5.4% NCT03924427 · Phase 3 · registry result, not featured evidence 12 mg QD blood creatine phosphokinase increased 15.9% (placebo 2.2%) acne 9.1% (placebo 0%) diarrhoea 9.1% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 6 mg BID nasopharyngitis 15.6% (placebo 4.4%) blood creatine phosphokinase increased 8.9% (placebo 2.2%) upper respiratory tract infection 8.9% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg BID nasopharyngitis 11.1% (placebo 4.4%) aphthous ulcer 6.7% (placebo 0%) headache 6.7% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QD nasopharyngitis 11.4% (placebo 4.4%) headache 9.1% (placebo 4.4%) psoriasis 6.8% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QOD headache 9.1% (placebo 4.4%) nausea 9.1% (placebo 4.4%) blood immunoglobulin e increased 6.8% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence | 40mg BIDa headache 7.7% (placebo 5.3%) nasopharyngitis 7.7% (placebo 7.9%) upper respiratory tract infection 7.7% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results40mg QD headache 10.3% (placebo 5.3%) acne 5.1% (placebo 0%) upper respiratory tract infection 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg BID headache 7.7% (placebo 5.3%) cough 5.1% (placebo 0%) diarrhea 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg QD headache 5.6% (placebo 5.3%) upper respiratory tract infection 5.6% (placebo 0%) acne 0% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 10mg QD diabetes mellitus 5.6% (placebo 0%) nasopharyngitis 5.6% (placebo 7.9%) upper respiratory tract infection 5.6% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
deucravacitinib
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 1 more result
+ 9 further endpoints in the CSV export.
Systemic Lupus Erythematosus
Shared mechanism: TYK2 · full Systemic Lupus Erythematosus pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2028 · NCT06875960 (registry estimate)
No aligned efficacy figure on record for this race.
Envudeucitinib
Developed by Alumis and partners
NCT05966480 · Phase 2 · active, not recruiting
The trial was well designed -- randomized, triple-blinded, placebo-controlled, and adequately sized (n=408) with a recognized disease-activity measure (BICLA) as its primary endpoint -- but the overall primary comparison did not reach statistical significance. A positive signal in one prespecified subgroup does not change the fact that the main, prespecified population analysis missed, so this remains solid but inconclusive evidence rather than strong evidence of a benefit.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). (missed)
Result source: NCT05966480
Results for Systemic Lupus Erythematosus
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | deucravacitinib | Envudeucitinib |
|---|---|---|
| SRI-4 | 44.9% vs 34.4%+10.5 vs placeboNCT032525875 other results
| —Not reported |
| BICLA | 36% vs 25.6%+10.4 vs placeboNCT032525872 other results
| —Not reported |
| CLASI-50 | 62.1% vs 16.7%+45.4 vs placeboNCT032525872 other results
| —Not reported |
| Steroid sparing | —Trial running · NCT05620407 | —Not reported |
SRI-4
- deucravacitinib
- 44.9% vs 34.4%+10.5 vs placeboNCT03252587
5 other results
- 49.5% vs 34.4% NCT03252587
- 58.2% vs 34.4% NCT03252587
- 47.2% vs 34.4% NCT03252587
- 47.3% vs 34.4% NCT03252587
- 57.1% vs 34.4% NCT03252587
- Envudeucitinib
- —Not reported
BICLA
- deucravacitinib
- 36% vs 25.6%+10.4 vs placeboNCT03252587
2 other results
- 35.5% vs 25.6% NCT03252587
- 47.3% vs 25.6% NCT03252587
- Envudeucitinib
- —Not reported
CLASI-50
- deucravacitinib
- 62.1% vs 16.7%+45.4 vs placeboNCT03252587
2 other results
- 56% vs 16.7% NCT03252587
- 69.6% vs 16.7% NCT03252587
- Envudeucitinib
- —Not reported
Steroid sparing
- deucravacitinib
- —Trial running · NCT05620407
- Envudeucitinib
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. deucravacitinib: 4 of 4 rows · Envudeucitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | deucravacitinib |
|---|---|
| Dropout rate | 39.7%12mg QDa NCT03920267 · Phase 2 · registry result, not featured evidence show 8 more results61.9%12mg QD NCT03920267 · Phase 2 · registry result, not featured evidence 39.7%6mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 38.1%6mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 37.3%3mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 57.1%3mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 30.3%12 mg NCT03252587 · Phase 2 · registry result, not featured evidence 18.3%6 mg NCT03252587 · Phase 2 · registry result, not featured evidence 22%3 mg NCT03252587 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 8.6%12mg QDa NCT03920267 · Phase 2 · registry result, not featured evidence show 8 more results9.5%12mg QD NCT03920267 · Phase 2 · registry result, not featured evidence 9.6%6mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 0%6mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 6%3mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 14.3%3mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 13.5%12 mg NCT03252587 · Phase 2 · registry result, not featured evidence 6.5%6 mg NCT03252587 · Phase 2 · registry result, not featured evidence 8.8%3 mg NCT03252587 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 22.4%12mg QDa NCT03920267 · Phase 2 · registry result, not featured evidence show 8 more results19%12mg QD NCT03920267 · Phase 2 · registry result, not featured evidence 12.3%6mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 0%6mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 16.4%3mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 14.3%3mg BID NCT03920267 · Phase 2 · registry result, not featured evidence 7.9%12 mg NCT03252587 · Phase 2 · registry result, not featured evidence 8.6%6 mg NCT03252587 · Phase 2 · registry result, not featured evidence 7.7%3 mg NCT03252587 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 12mg QDa covid-19 27.6% nasopharyngitis 22.4% upper respiratory tract infection 19% NCT03920267 · Phase 2 · registry result, not featured evidence show 8 more results12mg QD covid-19 19% nasopharyngitis 19% acne 14.3% NCT03920267 · Phase 2 · registry result, not featured evidence 6mg BID covid-19 28.8% urinary tract infection 21.9% upper respiratory tract infection 15.1% NCT03920267 · Phase 2 · registry result, not featured evidence 6mg BID nasopharyngitis 23.8% covid-19 19% diarrhoea 19% NCT03920267 · Phase 2 · registry result, not featured evidence 3mg BID covid-19 35.8% nasopharyngitis 19.4% upper respiratory tract infection 19.4% NCT03920267 · Phase 2 · registry result, not featured evidence 3mg BID covid-19 23.8% urinary tract infection 14.3% acne 9.5% NCT03920267 · Phase 2 · registry result, not featured evidence 12 mg headache 12.4% (placebo 16.7%) nasopharyngitis 9% (placebo 12.2%) upper respiratory tract infection 9% (placebo 8.9%) NCT03252587 · Phase 2 · registry result, not featured evidence 6 mg upper respiratory tract infection 19.4% (placebo 8.9%) nasopharyngitis 14% (placebo 12.2%) acne 8.6% (placebo 4.4%) NCT03252587 · Phase 2 · registry result, not featured evidence 3 mg upper respiratory tract infection 14.3% (placebo 8.9%) urinary tract infection 11% (placebo 3.3%) nasopharyngitis 8.8% (placebo 12.2%) NCT03252587 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
deucravacitinib
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · Envudeucitinib's landscape